Indivior lowers 2024 revenue forecast due to decreased SUBLOCADE sales amid competition.

Indivior PLC has reduced its 2024 revenue forecast due to disappointing sales of its opioid addiction treatment, SUBLOCADE, which faced competition from a rival product. As a result, shares fell by about 15% in London and 17% in pre-market trading on Nasdaq. The company now expects adjusted operating profit between $260 million and $280 million and annual net revenues of $1.125 billion to $1.165 billion, down from prior estimates.

October 10, 2024
6 Articles

Further Reading